期刊文献+

高密度脂蛋白亚组分促胆固醇逆转运及抗氧化功能研究 被引量:14

Research for Promoting Reverse Cholesterol Transportation and Anti-Oxidation Function ofHigh Density Lipoprotein Sub Classes in ACS Patients
下载PDF
导出
摘要 目的:明确急性冠状动脉(冠脉)综合征(ACS)患者高密度脂蛋白(HDL)亚组分(HDL2和HDL3)的促胆固醇逆转运及抗氧化功能是否发生了损害;同时探讨HDL2和HDL3抗动脉粥样硬化作用的强弱。方法:入选年龄及性别匹配的ACS患者(ACS组)及健康体检者(对照组)各40例,分别检测两组血脂四项、高敏C-反应蛋白、巨噬细胞氚三胆固醇转出率、脂氢过氧化物(LOOH)水平。结果:与对照组比较,ACS组HDL亚组分(HDL2和HDL3)介导的巨噬细胞氚三胆固醇转出率均明显下降;HDL亚组分LOOH水平则均较对照组明显升高;对照组和ACS组同组内,HDL3介导的巨噬细胞氚三胆固醇转出率均低于HDL2,HDL3-LOOH水平高于HDL2-LOOH。上述比较差异均有统计学意义(P<0.05~0.001)。结论:ACS患者HDL亚组分促胆固醇逆转运及抗氧化功能受到了损害,较对照组明显减弱;成熟的HDL2较未成熟的HDL3具有更强的促胆固醇逆转运及抗氧化功能。 Objective : To explicit the possible impairments of promoting reverse cholesterol transportation (RCT) and anti-oxidation function of high density lipoprotein(HDL) sub classes( HDL2 and HDL3 )in patients with acute coronary syndromes(ACS) and to explore the functional difference between I-IDL2 and HDL3. Methods :There were 2 groups enrolled in our study, ACS group and Healthy control group, n = 40 in each group. Plasma lipids and HDL sub classes of HDL2 and HDL3, hs-CRP Levels, cholesterol efflux capacity and LOOH levels were examined and compared between 2 groups. Results:Compared with Healthy control group, the HDL2 and HDL3 in ACS group showed decreased cholesterol efflux capacity and increased LOOH level. Within ACS group, the cholesterol efflux capacity in HDL3 was lower than that in HDL2 ,while the HDL3-LOOH level was higher, P〈0.05 -0.001 respectively. Conclusion:RCT and anti-oxidation functions of I-IDL2 and HDL3 were impaired in ACS patients, and those functions were strouger in HDL2 than that in HDL3.
出处 《中国循环杂志》 CSCD 北大核心 2013年第1期25-28,共4页 Chinese Circulation Journal
基金 广东省自然科学基金(10151051501000073) 教育部高等学校博士学科点专项科研基金(20104433110006)
关键词 急性冠脉综合征 高密度脂蛋白 亚组分 胆固醇转出率 脂氢过氧化物 Acute coronary syndrome High density lipoprotein Sub class Cholesterol efflux capacity LOOH
  • 相关文献

参考文献17

  • 1Ansell BJ,Watson KE,Fogelman AM. High-density lipoprotein function recent advances[J].Journal of the American College of Cardiology,2005,(10):1792-1798.doi:10.1016/j.jacc.2005.06.080.
  • 2deGoma EM,deGoma RL,Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches[J].Journal of the American College of Cardiology,2008.2199-2211.
  • 3Sviridov D,Mukhamedova N,Remaley AT. Antiatherogenic functionality of high density lipoprotein:how much versus how good[J].Journal of Atherosclerosis and Thrombosis,2008.52-62.
  • 4Shao B,Oda MN,Oram JF. Myeloperoxidase:an inflammatory enzyme for generating dysfunctionalhigh density lipoprotein[J].Current Opinion in Cardiology,2006.322-328.
  • 5Heinecke JW. The HDL proteome:a marker-and perhaps mediator-of coronary artery disease[J].Journal of Lipid Research,2009.S167-S171.
  • 6Karlsson H,Leanderson P,Tagesson C. Lipoproteomics Ⅱ:Mapping of proteins in high-density lipoprotein using two-dimensional gel-electrophoresis and mass spectrometry[J].Proteomics,2005.1431-1445.
  • 7Berrougui H,Isabelle M,Cloutier M. Age-related impairment of HDL-mediated cholesterol efflux[J].Journal of Lipid Research,2007.328-336.
  • 8Nourooz-Zadeh J,Tajaddini-Sarmadi J,Wolff SP. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-oxylenol orange assay in conjunction with triphenylphosphin[J].Analytical Biochemistry,1994.403-409.
  • 9Khera AV,Cuchel M,de la Llera-Moya M. Cholesterol efflux capacity,high-density lipoprotein function,and atherosclerosis[J].New England Journal of Medicine,2011.127-135.
  • 10Alwaili K,Bailey D,Awan Z. The HDL proteome in acute coronary syndromes shifts to an infl ammatory profl le[J].Biochimica Et Biophysica Acta,2012.405-415.

二级参考文献18

  • 1严晓伟,陈连凤,江恬.阿托伐他汀钙和非诺贝特酸对2型糖尿病患者泡沫细胞胆固醇外流的影响[J].中华老年心脑血管病杂志,2006,8(5):292-295. 被引量:5
  • 2朱颖,严晓伟,陈连凤,王晋峰,方全.阿托伐他汀对金黄地鼠糖尿病模型巨噬细胞胆固醇外流的影响[J].中国临床药理学与治疗学,2006,11(12):1355-1359. 被引量:1
  • 3Miller GJ, and Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet, 1975,1 : 16-19.
  • 4Toth PP. High-density lipoprotein and cardiovascular risk. Circulation,2004,109(15) :1809-1812.
  • 5Ansell BJ, Watson KE, Fogelman AM, et al. High-density lipoprotein function recent advances. J Am Coll Cardiol, 2005, Nov 15 ; 46 (10):1792-1798. Epub 2005 Oct 19.
  • 6Kontush A,Chapman MJ. Functionally defective high-density lipoprotein:a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev ,2006,58 : 342-374.
  • 7Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest,2006,116 (12) :3090-3100.
  • 8Nobecourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small,dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycemia. Diabetologia ,2005,48:529-538.
  • 9Madjid M, Naghavi M, Litovsky S, et al. Influenza and cardiovascular disease. Circulation ,2003,108 : 2730-2736.
  • 10McMahon M, Naghavi M, Litovsky S, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum, 2006,54(8):2541-2549.

共引文献6

同被引文献203

引证文献14

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部